Kidswell Bio Corporation
4584 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 中央区新川一丁目２番１２号
- Website:
- https://www.kidswellbio.com/en/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Kidswell Bio Corporation is a pioneering Japanese biotechnology firm dedicated to developing innovative solutions for pediatric healthcare. With a mission encapsulated in the phrase "KIDS WELL, ALL WELL," the company focuses on advancing biologics, biosimilars, and groundbreaking cell therapies to address critical medical needs. Kidswell Bio's robust pipeline includes promising research in treatments for conditions such as pediatric cerebral palsy and spinal cord injuries, utilizing its proprietary SHED technology. Committed to improving the quality of life for children, Kidswell Bio combines scientific expertise with a compassionate vision for the future, aiming to create a healthier world for the next generation.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-30 08:33 |
Inside Information Statement
臨時報告書
|
Japanese | 24.0 KB | |
| 2025-06-27 08:36 |
Regulatory News Service
確認書
|
Japanese | 8.0 KB | |
| 2025-06-27 08:35 |
Internal Control over Financial Reporting
内部統制報告書－第25期(2024/04/01－2025/03/31)
|
Japanese | 22.2 KB | |
| 2025-06-27 08:33 |
Annual Report
有価証券報告書－第25期(2024/04/01－2025/03/31)
|
Japanese | 1.2 MB | |
| 2025-03-31 09:16 |
Inside Information Statement
臨時報告書
|
Japanese | 18.2 KB | |
| 2024-12-26 07:56 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 543.7 KB | |
| 2024-11-14 07:50 |
Regulatory News Service
確認書
|
Japanese | 8.0 KB | |
| 2024-11-14 07:47 |
Interim Report
半期報告書－第25期(2024/04/01－2025/03/31)
|
Japanese | 185.0 KB | |
| 2024-06-27 09:12 |
Inside Information Statement
臨時報告書
|
Japanese | 22.5 KB | |
| 2024-06-27 09:11 |
Internal Control over Financial Reporting
内部統制報告書－第24期(2023/04/01－2024/03/31)
|
Japanese | 21.2 KB | |
| 2024-06-27 09:11 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-06-27 09:10 |
Annual Report
有価証券報告書－第24期(2023/04/01－2024/03/31)
|
Japanese | 1.1 MB | |
| 2024-06-07 08:39 |
Regulatory News Service
確認書
|
Japanese | 8.1 KB | |
| 2024-06-07 08:36 |
Regulatory News Service
訂正有価証券報告書－第23期(2022/04/01－2023/03/31)
|
Japanese | 692.5 KB | |
| 2024-02-14 07:35 |
Regulatory News Service
確認書
|
Japanese | 8.0 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nippon Shinyaku Co.,Ltd. | Japan | 4516 | |
|
Noile-Immune Biotech Inc. | Japan | 4893 | |
|
Novartis AG | Switzerland | NOVN | |
|
Nur Ink Innovations Ltd. | Israel | NURI | |
|
Nxera Pharma Co., Ltd. | Japan | 4565 | |
|
ObsEva SA | Switzerland | OBSN | |
|
ODI Pharma AB | Sweden | ODI | |
|
Oncolys BioPharma Inc. | Japan | 4588 | |
|
OncoTherapy Science, Inc. | Japan | 4564 | |
|
OncoZenge AB | Sweden | ONCOZ |